<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04061213</url>
  </required_header>
  <id_info>
    <org_study_id>4083 / KEK-Nr. 2019-00880</org_study_id>
    <nct_id>NCT04061213</nct_id>
  </id_info>
  <brief_title>ATTR Amyloidosis in Elderly Patients With Aortic Stenosis</brief_title>
  <official_title>ATTR Amyloidosis in Elderly Patients With Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe aortic stenosis is defined with a mean transvalvular pressure gradient (MTPG) &gt; 40mmHg
      and a calculated aortic valve area of &lt; 1cm2. However, a considerable proportion of patients
      do have a MTPG &lt; 40mmHg due to a reduced stroke volume (stroke volume indexed to body surface
      area â‰¤ 35ml/m2) despite a normal left ventricular ejection fraction (LVEF &gt; 50%). This entity
      is termed paradoxical low flow low gradient aortic stenosis (PLFLG AS) and is associated with
      a worse prognosis.

      ATTR amyloidosis is a disease of the elderly and might coexist in patients with severe aortic
      stenosis. Case reports and small observational studies suggest that senile ATTR amyloidosis
      could be frequent but underdiagnosed in patients with aortic stenosis. There is significant
      overlap between PLFLG AS and cardiac amyloidosis with regard to symptoms, increasing
      prevalence with age, concentric hypertrophy, impaired diastolic filling of the left ventricle
      (LV), as well as longitudinal LV dysfunction despite preserved ejection fraction - all
      features, which lead to a reduction in stroke volume, the underlying mechanism of the low
      flow condition as observed in PLFLG AS patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Proportion of patients with grade 2 or 3 cardiac uptake in scintigraphy and without pathological light chains in immunological assays</measure>
    <time_frame>In-Hospital [7 days]</time_frame>
    <description>Evaluation of incidence rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause and cardiovascular mortality</measure>
    <time_frame>30 days, 12months</time_frame>
    <description>Clinical Endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CPET - maximal exercise capacity</measure>
    <time_frame>In-Hospital [7 days]</time_frame>
    <description>Functional Endpoints</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Aortic Stenosis Symptomatic</condition>
  <condition>Amyloidosis Cardiac</condition>
  <arm_group>
    <arm_group_label>Patients with symptomatic severe aortic stenosis</arm_group_label>
    <description>Elderly patients referred for TAVR evaluation</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Tc-99m-DPD scintigraphy</intervention_name>
    <description>Myocardial scintigraphy</description>
    <arm_group_label>Patients with symptomatic severe aortic stenosis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with symptomatic, severe aortic stenosis undergoing pre-evaluation for
        (transcatheter) aortic valve replacement
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic, severe aortic stenosis

        Exclusion Criteria:

          -  More than mild valvular disease of any other valve

          -  Other severe disease with a life expectancy &lt; 1 year

          -  Participating in trial interfering with routine clinical practice or use of a non-CE
             marked device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Stortecky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swiss Cardiovascular Center Bern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Stortecky, MD</last_name>
    <phone>0041 31 632 83 52</phone>
    <email>stefan.stortecky@insel.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Bern - Inselspital</name>
      <address>
        <city>Bern</city>
        <state>BE</state>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Stortecky, MD</last_name>
      <phone>0041 31632 83 52</phone>
      <email>stefan.stortecky@insel.ch</email>
    </contact>
    <contact_backup>
      <last_name>Stephan Dobner, MD</last_name>
      <phone>0041 31 632 21 11</phone>
      <email>stephan.dobner@insel.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 15, 2019</study_first_submitted>
  <study_first_submitted_qc>August 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2019</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Technetium Tc 99m 1,1-diphosphonopropane-2,3-dicarboxylic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

